Shandong Xinchuang Biotechnology Co., Ltd. has recently received the notice on the project initiation of the 2019 annual implementation plan of major new drug creation science and technology major project (health science special letter (2019) No. 764) issued by the medical and Health Science Development Research Center of the National Health Commission. The special subject of "research and development of lyophilized spore powder of Clostridium gloeosporioides, a new class of new drug for nasopharyngeal carcinoma", has been highly valued by the state, and has been listed in the national "major new drug creation" major scientific and technological special project, and has been funded by the central government.
The major scientific and technological project of "major new drug creation" is jointly set up by the Ministry of science and technology, the development and Reform Commission and the Ministry of finance. It aims to break through a number of core key technologies that restrict the creation of new drugs, and produce a batch of innovative achievements with great clinical value and urgently needed chemical drugs, traditional Chinese medicine and biological drugs To form a unique national drug innovation system. At the same time, it puts forward higher requirements on the scientific research ability and experimental conditions of the enterprises undertaking the project.
Oncolytic bacteria as a new direction after oncolytic virus, especially the anti-tumor effect of anaerobes is rising in the world. It has been found that oncolytic bacteria have high safety, wide indications, high killing rate, a variety of ways to avoid drug resistance and low cost, which is expected to become one of the most potential and application prospects of cancer treatment methods in the future.
At present, we have won the first international invention patent award of Clostridium freeze-dried powder in China and other countries. Now it has entered the stage of clinical trial, and will complete phase I clinical trial in 2020, striving to become the first listed bacterial tumor drug in the world.
The project was included in the national science and technology major project, which highly recognized the company's R & D capability, independent innovation level and innovation achievements. Meanwhile, the enthusiasm for domestic bacterial oncolytic drug research and development was unprecedented high, which laid a solid foundation for tumor patients in China to use more effective and more economical new oncolytic drugs as soon as possible.